Loading
FDA contradicts Peruvian Health Minister: “Anti-implantation” effect of morning after pill not ruled out

.- A spokeswoman for the Food and Drug Administration (FDA) has told CNA that the government agency has not ruled out the anti-implantation effect of Levonorgestrel—the generic name for the morning after pill—because it has not received “safety information” to make such a determination. This week Peruvian Minister of Health, Pilar Mazzetti, told reporters the FDA data on the abortion pill is from 2002 and that “recent studies” confirm that the drug’s third mechanism—which is the focal point of the controversy—has been ruled out.

An FDA statement from May 7, 2004, said the morning after pill functions primarily by preventing ovulation, but it can also prevent fertilization, and if fertilization has already taken place, it can prevent the fertilized ovum from implanting itself in the uterus.

This third mechanism is what has caused the controversy in Peru because the Peruvian constitution grants protection to human life from the moment of conception, not implantation.  By denying the anti-implantation effect, Mazzetti is attempting to get around charges that her decision to distribute the drug as part of family planning policy is unconstitutional.

According to Susan Cruzan, public relations specialist of the FDA, the agency’s statement of May 7, 2004, only reiterates that the first mechanism—prevention of ovulation—is the only one that has been confirmed.  The possibility that the drug prevents fertilization and implantation has not been ruled out.

Asked about the recent studies cited by Mazzetti, Cruzan said, “It’s really up to the manufacturer to submit that information to the Food and Drug Administration” because “the manufacturers are the ones that should make the labeling changes.”

“What you can do is call the company and make sure that they have that data and essentially the companies are required to send any new info that is related to the Food and Drug Administration, specifically if it relates to safety information.  So again it’s really up to the manufacturer to submit that information to the food and drug administration and certainly people can call that to our attention,” said Cruzan.

She added that “the way that FDA operates, the FDA will have to see those studies and review them to make a determination based on that.  We make our decisions based on science and the data that is submitted to the agency.”

In addition, Cruzan said that “what would have to happen in order for FDA to change the information that is put out there is that the company would have to submit that data and FDA would then have to update the label.”

“Its a scientific review process,” Cruzan said.  “You can’t just say that, ‘Oh well you heard through us’.  Usually what happens is that it will have to go through the actual manufacturers of those products. You know the manufacturers are the ones that should make the labeling changes.”


Ads by AdsLiveMedia(What's this?)

* The number of messages that can be online is limited. CNA reserves the right to edit messages for content and tone. Comments and opinions expressed by users do not necessarily reflect the opinions or beliefs of CNA. CNA will not publish comments with abusive language, insults or links to other pages

RESOURCES »

Ads by Google (What's this?)
Ads by Google (What's this?)

Featured Videos

Pope Francis celebrates the closing Mass and announces site of next World Youth Day
Pope Francis celebrates the closing Mass and announces site of next World Youth Day
Pope Francis visits poor neighborhood and meets with young people from Argentina
Pope Francis celebrates Mass at the National Shrine of Our Lady of Aparecida
Denver rally draws hundreds in support of religious freedom
Pope Francis prays over a sick man in St Peter's Square
Denver women's clinic will offer natural, Catholic care
Interview Clips: Barbara Nicolosi speaks to CNA
US Cardinals press conference at North American College
Pope Benedict to retire to monastery inside Vatican City
Pope cites waning strength as reason for resignation
Hundreds convene in Denver to urge respect for life
New Orange bishop encourages Catholic unity in diversity
Chinese pro-life activist calls for reform, international attention
At Lincoln installation, Bishop Conley says holiness is success
Mother Cabrini shrine reopens in Chicago after a decade
Ordination of 33 deacons fills St. Peter's with joy
Cardinal says "Charity is the mother of all the virtues"
Augustine Institute expands evangelization effort with new campus
Bishops recall 'Way of St. James' as chance to trust in God
Los Angeles cathedral's newest chapel houses Guadalupe relic
Apr
21

Liturgical Calendar

April 21, 2014

Monday within the Octave of Easter

All readings:
Today »
This year »

Catholic Daily

Gospel of the Day

Mt 28:8-15

Gospel
Date
04/21/14
04/20/14
04/19/14

Daily Readings


First Reading:: Acts 2:14, 22-33
Gospel:: Mt 28:8-15

Saint of the Day

Holy Thursday »

Saint
Date
04/21/14

Homily of the Day

Mt 28:8-15

Homily
Date
04/21/14
04/20/14
04/19/14

Ads by AdsLiveMedia.com

Ads by AdsLiveMedia.com
     HTML
Text only
Headlines
  

Follow us: